Gilead Raises Revenue Outlook but Guides to a Loss on Acquisition Costs

What happened

Gilead reported a Q1 2026 beat and raised its full-year sales forecast, but slashed its profit outlook to a GAAP loss due to acquisition-related charges and financing costs. The headline revenue growth is positive, but the profit cut underscores the dilutive near-term impact of deal-making. This does not alter the fundamental thesis that Yeztugo PrEP adoption and HIV pricing headwinds are the key drivers. The DeepValue report already flagged that margin of safety is limited and that the stock trades on Yeztugo execution, not multiple expansion. The profit guidance cut is a reminder that acquisitions can erode near-term EPS even as top-line accelerates.

Implication

The profit cut is largely non-operational (acquisition charges) and does not change the core HIV-cash-flow story. However, it increases reliance on non-GAAP metrics to mask dilution. Investors should focus on Yeztugo covered-lives and re-dosing rates, not GAAP near-term figures. The thesis remains contingent on the $800M 2026 target, which the raised sales forecast supports. We maintain a WAIT rating until Q2 results provide clarity on payer access and persistence.

Thesis delta

The news reinforces the status quo: Gilead's HIV cash engine remains strong, but the profit outlook cut due to deal costs highlights that management is willing to trade near-term earnings for long-term pipeline bets. This does not shift the core thesis—Yeztugo execution remains the swing factor. If anything, the lowered profit bar makes beating estimates easier, but it also raises scrutiny on how quickly acquisitions contribute. The thesis delta is neutral: the wait-and-see stance on Yeztugo is unchanged.